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diseases are not linked to abnormalities of protein coding genes (PCGs), but of non-coding RNAs (ncRNAs).
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protein coding gene is known, thus suggesting that miRNAs might be the elusive culprits. Our ﬁndings
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The Online Mendelian Inheritance in Man database (OMIM, http://
www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM) contains informa-
tion, including responsible PCGs, phenotypes, linkage data and
references, on all human inherited or heritable disorders. Considered
aphenotypic companion to thehumangenomeproject, and asofAugust
2010, OMIM comprised 4613 Mendelian diseases (which are preﬁxed
using ‘#’ (n=2837) if the responsible gene is known and with ‘%’
otherwise (n=1776)), 367 genes with an associated phenotype
(preﬁxed using ‘+’), and 13173 genes (including 183 microRNAs)
with known sequence (preﬁxed using ‘*’).
MicroRNAs (miRNAs) are small RNA molecu'les typically between
19 and 22 nucleotides in length that act as negative regulators of gene
expression and are produced from larger primary transcripts (pri-
miRNAs) [1]. In animal cells, miRNAs bind the RNA-induced silencingcomplex (RISC) and speciﬁc target messenger RNAs (mRNAs), which
either remain untranslated or are degraded [2]. Many investigators
have reported that miRNAs are critical in stem cell function [3] and
tissue development [4], are involved in viral infections [5] and are
associated with oncogenesis [6–9]. Furthermore, we previously
reported that miRNAs are frequently located at human Cancer
Associated Genomic Regions (CAGRs), such as ampliﬁed or deleted
regions [10] or mouse modiﬁer loci [11]. Mattick and colleagues
recently reported that orthologous miRNA genes are located in CAGRs
in human and mouse [12]. However, with the exception of X-linked
mental retardation [13], miRNAs have not been thought of as possible
causal of Mendelian diseases. To test the hypothesis that somemiRNAs
could be potentially responsible for a number of “orphan” Mendelian
diseases, we developed the OMiR method and used it to conduct a
bioinformatics study.2. Methods
2.1. OMIM Morbid Map
The Morbid Map is an alphabetical list of diseases described in
OMIM with their corresponding cytogenetic locations and related
mapping studies and references (http://www.ncbi.nlm.nih.gov/
Omim/getmorbid.cgi).WeusedMorbidMap to extract OMIM identiﬁca-
tions (IDs) and corresponding disease names and loci. Information for
Fig. 1. The ﬁve steps of OMiR algorithm: 1) OMIM ID information extraction and
conversion; 2) Overlap between miRNAs or Protein Coding Genes loci and OMIM loci;
3) 10,000 randomly reshufﬂed overlaps, 4) P-value and Q value calculation; and
5) Extraction of the signiﬁcant overlaps.
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from cytogenetic location to base position using the UCSC Table
Browser (available at http://genome.ucsc.edu/cgi-bin/hgTables, March
2006 release). We focused on: a) entries with a conﬁrmed Mendelian
phenotype or phenotypic locus for which the underlying molecular
basis is not known (the diseases are preﬁxed with ‘%’) and b) descriptive
entries, usually of a phenotype with known molecular basis that does
not represent a unique locus (preﬁxed with ‘#’). For statistical purposes,
we considered as unknowns the OMIM diseases with a ‘%’ preﬁx and
as controls the ‘#’ preﬁxed OMIM diseases because the genes responsible
for them are known (and are not miRNAs). We examined also the
OMIM diseases with preﬁx ‘*’ (a gene of known sequence) and ‘+’
(a known gene and corresponding phenotype) as controls. If an
OMIM ID was associated to more than one locus, each locus was tested
separately.Fig. 2. Ratios between the percentage of signiﬁcant OMIM::miRNAs associations and OMIM
‘#’ molecular basis known and ‘*’ and ‘+’, known sequence and/or phenotype.2.2. Extraction and management of miRNA information
The names, chromosome location, start and end positions of 939
miRNAs were downloaded from miRBase release 15.0 (ftp://mirbase.
org/pub/mirbase/CURRENT/genomes/hsa.gff). Because each miRNA
maps to a much smaller region (about 100 nt) than that mapped to
the disease (millions of bp), if two or more miRNAs are signiﬁcantly
associated with an OMIM locus, then they are considered (a posteriori)
as a relevant cluster.
2.3. Identifying signiﬁcant associations of microRNAs and PCGs with
OMIM disease loci
For a given OMIM locus, we computed its overlap (i.e. the number
of common nucleotides between the miRNAs and the OMIM locus)
with the loci of knownmiRNA transcripts. The probability (p-value) of
the observed overlap was computed given the empirical null
distribution of overlaps, which was estimated using 10,000 randomly
reshufﬂed versions of the miRNA loci on each chromosome of the
genome: each reshufﬂed set of loci yielded an overlap value, and all
these overlaps comprise the empirical null distribution of overlaps.
Finally, the false discovery rate (FDR) was calculated by comparing
the distribution of p-values against the empirical null distribution of
expected p-values, which was estimated using the same 10,000
randomly reshufﬂed miRNA loci. As before, each reshufﬂed version
yields an overlap value, whose p-value can be computed using the
entire set of 10,000 overlap values. All these p-values comprise the
empirical null distribution of p-values. This method has been applied
to miRNAs and PCGs' transcript loci independently in order to
compare the relative number of statistically signiﬁcant associations
obtained. Human ENSEMBL release 54 was used to obtain the PCG loci
and miRBase 15.0 to obtain miRNAs loci.
2.4. MiRNA target analysis
AmiRNA target analysiswasperformed todetermine if the identiﬁed
associations could reveal whether the functions of mRNA targets could
be related to the associated disease. Using the David Bioinformatics
Resources system (http://david.abcc.ncifcrf.gov), we compared the list
of terms related to the predicted targeted mRNAs. The terms were
evaluated by Bonferroni p-value correction (Pb0.05). We evaluated
Gene Ontology (biological process, molecular function and cellular
component, http://www.geneontology.org/), INTERPRO (http://www.
ebi.ac.uk/interpro/), PATHWAY (http://www.biocarta.com/ and http://
www.genome.jp/kegg/), UP_TISSUE (http://david.abcc.ncifcrf.gov/)
and SP_PIR_KEYWORDS (functional category) and OMIM disease
(http://www.ncbi.nlm.nih.gov/omim/). The predicted targeted mRNAs
were retrieved using miRGen (http://www.diana.pcbi.upenn.edu/data/::mRNAs associations, for each OMIM ID type studied: ‘%’, molecular basis unknown,
Table 1
Six signiﬁcant association between % OMIM IDs and miRNAs.
OMIM-ID Description and locus Expected
genes
Associated
genes
P-value Q-value miRNA symbols RNA22 and miRGen target terms
(David, Bonferroni Pb0.05)
%609572 Photoparoxysmal response 2;
PPR2; photoparoxysmal
response with or without
idiopathic generalized
epilepsy; gene map locus
13q31.3;
0.92 7 0 0 mir-17 mir-18a mir-19a mir-19b-1
mir-20a mir-622 mir-92a-1
GO: cell death, apoptosis, cell
differentiation, cell development,
regulation of cellular metabolic process,
transmembrane receptor protein
tyrosine kinase signaling pathway,
anatomical structure morphogenesis,
regulation of gene expression,
regulation of transcription from RNA;
INTERPRO: serine/threonine protein
kinase; SP_PIR_KEYWORDS: serine/
threonine-protein kinase; TISSUE: brain,
fetal brain.
%300509 Dyslexia, susceptibility to, 9;
DYX9; genemap locus Xq27.3;
DXS8043
2.88 21 b0.0001 0 mir-506mir-507mir-508mir-509-1mir-
509-2 mir-509-3 mir-510 mir-513a-1
mir-513a-2 mir-513b mir-513c mir-
514-1 mir-514-2 mir-514-3 mir-888
mir-890 mir-891a mir-891b mir-892a
mir-892b
GO: developmental process,
anatomical structure development,
multicellular organismal development,
system development, nervous system
development; TISSUE: brain.
%300244 Terminal osseous dysplasia
and pigmentary defects;
TODPD; gene map locus
Xq27.3-q28
7.47 34 b0.0001 0 mir-105-1 mir-105-2 mir-1184 mir-
224 mir-452 mir-506 mir-507 mir-508
mir-509-1 mir-509-2 mir-509-3 mir-
510 mir-513a-1 mir-513a-2 mir-513b
mir-513c mir-514-1 mir-514-2 mir-
514-3 mir-767 mir-888 mir-890 mir-
891a mir-891b mir-892a mir-892b
GO: developmental process,
anatomical structure development,
multicellular organismal development,
nervous system development, cellular
developmental process, cell
differentiation, anatomical structure
morphogenesis; UP_SEQ_FEATURE:
mutagenesis site; TISSUE: brain,
epithelium, fetal brain.
%300388 Polymicrogyria, Bilateral
Perisylvian; BPP; gene map
locus Xq27.2-q28; DXS8103
and Xqter
8.52 35 b0.0001 0 mir-105-1mir-105-2mir-1184mir-224
mir-452 mir-506 mir-507 mir-508 mir-
509-1 mir-509-2 mir-509-3 mir-510
mir-513a-1 mir-513a-2 mir-513b mir-
513c mir-514-1 mir-514-2 mir-514-3
mir-767 mir-888 mir-890 mir-891a
mir-891b mir-892a mir-892b
GO: cellular component organization
and biogenesis, developmental process,
anatomical structure development,
regulation of biological process, system
development, multicellular organismal
development, nervous system
development, cellular developmental
process, cell differentiation, anatomical
structure morphogenesis, cell
development, synapse; INTERPRO: SRC
homology-3, Pleckstrin-like, Pleckstrin
homology-type, serine/yhreonine
protein kinase; KEGG_PATHWAY:
calcium signaling pathway;
SP_PIR_KEYWORDS: disease mutation,
proto-oncogene, serine/threonine-
protein kinase, cytoskeleton,
magnesium; UP_SEQ_FEATURE:
mutagenesis site; TISSUE: brain,
epithelium, fetal brain, melanoma.
%608423 Muscular dystrophy, limb-
girdle, type 1F; LGMD1F; gene
map locus 7q32.1-q32.2;
D7S2544
0.99 6 0 0.01 mir-129-1 mir-182 mir-183 mir-335
mir-593 mir-96
GO: anatomical structure
development, developmental process,
system development, multicellular
organismal development, anatomical
structure morphogenesis, organ
development, nervous system
development, organ morphogenesis;
INTERPRO: plekstrin homology-type;
SO_PIR_KEYWORDS: cytoskeleton;
TISSUE: brain, muscle.
%300614 Deafness, X-linked 5; DFNX5;
gene map locus Xq23-q27.3;
DXS1220 and DXS8084
22.03 48 b0.0001 0 mir-106a mir-1264 mir-1277 mir-
1298 mir-18b mir-1911 mir-1912 mir-
19b-2 mir-20b mir-220a mir-320d-2
mir-363 mir-424 mir-448 mir-450a-1
mir-450a-2 mir-450b mir-503 mir-504
mir-505 mir-506 mir-507 mir-508
mir-509-1 mir-509-2 mir-509-3 mir-
510 mir-513a-1 mir-513a-2 mir-513b
mir-513c mir-514-1 mir-514-2 mir-
514-3 mir-542 mir-766 mir-888 mir-
890 mir-891a mir-891b mir-892a mir-
892b mir-92a-2 mir-934
GO: developmental process,
anatomical structure development,
system development, multicellular
organismal development, cellular
developmental process, organ
development, cell death, nervous
system development, anatomical
structure morphogenesis,
programmed cell death, apoptosis,
regulation of programmed cell death,
regulation of apoptosis, regulation of
gene expression, dephosphorylation;
INTERPRO: serine/threonine protein
kinase, serine/threonine protein
kinase, active site;
SP_PIR_KEYWORDS: disease mutation;
Tissue: fetal brain.
(continued on next page)
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Table 1 (continued)
OMIM-ID Description and locus Expected
genes
Associated
genes
P-value Q-value miRNA symbols RNA22 and miRGen target terms
(David, Bonferroni Pb0.05)
%138900 Uric acid concentration, serum,
quantitative trait locus 1;
UAQTL1; gout susceptibility 1;
genemap locus 4q25; D4S2623
1.14 8 0.0001 0 mir-297 mir-302a mir-302b mir-302c
mir-302d mir-367 mir-576
%152430 Longevity 1; gene map locus
4q25; D4S1564
1.14 8 0.0001 0 mir-297 mir-302a mir-302b mir-302c
mir-302d mir-367 mir-576
%611494 Atrial ﬁbrillation, familial, 5;
ATFB5; gene map locus 4q25;
rs2200733; rs2200733 and
rs10033464
1.14 8 0.0001 0 mir-297 mir-302a mir-302b mir-302c
mir-302d mir-367 mir-576
%610840 Mitral valve prolapse,
myxomatous 3; MMVP3; gene
map locus 13q31.3-q32.1;
D13S132
1.5 7 0 0 mir-17 mir-18a mir-19a mir-19b-1
mir-20a mir-622 mir-92a-1
GO: cell death, apoptosis, cell
differentiation, cell development,
regulation of cellular metabolic
process, transmembrane receptor
protein tyrosine kinase signaling
pathway, anatomical structure
morphogenesis, regulation of gene
expression, regulation of transcription
from RNA; INTERPRO: serine/
threonine protein kinase;
SP_PIR_KEYWORDS: disease mutation,
serine/threonine-protein kinase,
magnesium, transcription regulation;
TISSUE: brain, eye, fetal brain.
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watson.ibm.com/rna22.html) with the following parameters: mini-
mumnumberof paired-upbases inheteroduplex=12,maximumfolding
energy for heteroduplex=−25 kcal/mol, maximum number of allowed
UN-paired bases=0 in seed/nucleus of 6 nucleotides.Table 2
RNA22 folding energy between genes related to %138900, %606460 and %611494 and OmiR
mRNA miRNA
gi|146260266|ref|NM_001455.3| FOXO3 miR-297
gi|146260266|ref|NM_001455.3| FOXO3 miR-297
gi|146260269|ref|NM_201559.2| FOXO3 miR-297
gi|146260269|ref|NM_201559.2| FOXO3 miR-297
gi|152963645|ref|NM_000325.5| PITX2 3 miR-297
gi|24234707|ref|NM_153426.1| PITX2 2 miR-297
gi|24234710|ref|NM_153427.1| PITX2 1 miR-297
gi|27894305|ref|NM_000576.2| IL1B miR-297
gi|27894331|ref|NM_000877.2| IL1R1 miR-297
gi|27894331|ref|NM_000877.2| IL1R1 miR-297
gi|27894331|ref|NM_000877.2| IL1R1 miR-297
gi|27894331|ref|NM_000877.2| IL1R1 miR-297
gi|73622112|ref|NM_001223.3| CASP1 miR-297
gi|73622114|ref|NM_033292.2| CASP1 miR-297
gi|146260266|ref|NM_001455.3| FOXO3 miR-302a
gi|146260269|ref|NM_201559.2| FOXO3 miR-302a
gi|208879433|ref|NM_183395.2| NLRP3 miR-302a
gi|208879433|ref|NM_183395.2| NLRP3 miR-302a
gi|208879434|ref|NM_004895.4| NLRP3 miR-302a
gi|208879434|ref|NM_004895.4| NLRP3 miR-302a
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302a
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302a
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302a
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302a
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302a
gi|27502389|ref|NM_001562.2| IL18 miR-302a
gi|73622111|ref|NM_033294.2| CASP1 miR-302a
gi|73622112|ref|NM_001223.3| CASP1 miR-302a
gi|73622114|ref|NM_033292.2| CASP1 miR-302a
gi|73622118|ref|NM_033293.2| CASP1 miR-302a
gi|146260266|ref|NM_001455.3| FOXO3 miR-302b
gi|146260269|ref|NM_201559.2| FOXO3 miR-302b
gi|208879433|ref|NM_183395.2| NLRP3 miR-302b
gi|208879433|ref|NM_183395.2| NLRP3 miR-302b
gi|208879434|ref|NM_004895.4| NLRP3 miR-302b
gi|208879434|ref|NM_004895.4| NLRP3 miR-302b3. Results
OMiR was implemented in perl and C++. First, we converted the
OMIM, miRNAs and PCGs information from cytogenetic regions in
base positions corresponding to various locations of OMIM diseasesassociated miRNA clusters.
Offset Folding energy (kcal/mol)
3797 to 3817 −27.00
6785 to 6805 −26.50
3770 to 3790 −27.00
6758 to 6778 −26.50
1831 to 1851 −26.40
1754 to 1774 −26.40
1616 to 1636 −26.40
427 to 447 −30.00
672 to 692 −25.20
4830 to 4850 −29.80
1036 to 1056 −26.50
4224 to 4244 −25.50
223 to 243 −25.10
223 to 243 −25.10
5946 to 5968 −25.70
5919 to 5941 −25.70
1807 to 1829 −25.00
231 to 253 −26.40
1807 to 1829 −25.00
231 to 253 −26.40
1807 to 1829 −25.00
231 to 253 −26.40
1841 to 1863 −25.00
265 to 287 −26.40
1199 to 1221 −25.00
997 to 1019 −29.50
371 to 393 −34.80
587 to 609 −34.80
650 to 672 −34.80
371 to 393 −34.80
5946 to 5968 −25.70
5919 to 5941 −25.70
1807 to 1829 −25.80
231 to 253 −26.40
1807 to 1829 −25.80
231 to 253 −26.40
Table 2 (continued)
mRNA miRNA Offset Folding energy (kcal/mol)
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302b 1807 to 1829 −25.80
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302b 231 to 253 −26.40
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302b 1841 to 1863 −25.80
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302b 265 to 287 −26.40
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302b 1199 to 1221 −25.80
gi|27502389|ref|NM_001562.2| IL18 miR-302b 997 to 1019 −30.40
gi|73622111|ref|NM_033294.2| CASP1 miR-302b 371 to 393 −35.30
gi|73622112|ref|NM_001223.3| CASP1 miR-302b 587 to 609 −35.30
gi|73622114|ref|NM_033292.2| CASP1 miR-302b 650 to 672 −35.30
gi|73622118|ref|NM_033293.2| CASP1 miR-302b 371 to 393 −35.30
gi|146260266|ref|NM_001455.3| FOXO3 miR-302c 7212 to 7234 −26.60
gi|146260269|ref|NM_201559.2| FOXO3 miR-302c 7185 to 7207 −26.60
gi|208879433|ref|NM_183395.2| NLRP3 miR-302c 811 to 833 −25.80
gi|208879433|ref|NM_183395.2| NLRP3 miR-302c 1807 to 1829 −28.32
gi|208879433|ref|NM_183395.2| NLRP3 miR-302c 231 to 253 −25.50
gi|208879434|ref|NM_004895.4| NLRP3 miR-302c 811 to 833 −25.80
gi|208879434|ref|NM_004895.4| NLRP3 miR-302c 1807 to 1829 −28.32
gi|208879434|ref|NM_004895.4| NLRP3 miR-302c 231 to 253 −25.50
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302c 811 to 833 −25.80
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302c 1807 to 1829 −28.32
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302c 231 to 253 −25.50
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302c 845 to 867 −25.80
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302c 1841 to 1863 −28.32
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302c 265 to 287 −25.50
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302c 203 to 225 −25.80
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302c 1199 to 1221 −28.32
gi|27502389|ref|NM_001562.2| IL18 miR-302c 997 to 1019 −32.60
gi|73622111|ref|NM_033294.2| CASP1 miR-302c 371 to 393 −33.20
gi|73622112|ref|NM_001223.3| CASP1 miR-302c 587 to 609 −33.20
gi|73622114|ref|NM_033292.2| CASP1 miR-302c 650 to 672 −33.20
gi|73622118|ref|NM_033293.2| CASP1 miR-302c 371 to 393 −33.20
gi|146260266|ref|NM_001455.3| FOXO3 miR-302d 1759 to 1781 −26.30
gi|146260266|ref|NM_001455.3| FOXO3 miR-302d 4768 to 4790 −29.50
gi|146260266|ref|NM_001455.3| FOXO3 miR-302d 5946 to 5968 −27.30
gi|146260269|ref|NM_201559.2| FOXO3 miR-302d 1732 to 1754 −26.30
gi|146260269|ref|NM_201559.2| FOXO3 miR-302d 4741 to 4763 −29.50
gi|146260269|ref|NM_201559.2| FOXO3 miR-302d 5919 to 5941 −27.30
gi|208879433|ref|NM_183395.2| NLRP3 miR-302d 2443 to 2465 −25.10
gi|208879433|ref|NM_183395.2| NLRP3 miR-302d 3797 to 3819 −26.50
gi|208879433|ref|NM_183395.2| NLRP3 miR-302d 231 to 253 −26.50
gi|208879434|ref|NM_004895.4| NLRP3 miR-302d 2443 to 2465 −25.10
gi|208879434|ref|NM_004895.4| NLRP3 miR-302d 4139 to 4161 −26.50
gi|208879434|ref|NM_004895.4| NLRP3 miR-302d 231 to 253 −26.50
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302d 2443 to 2465 −25.10
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302d 3968 to 3990 −26.50
gi|208879435|ref|NM_001127462.2| NLRP3 miR-302d 231 to 253 −26.50
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302d 2477 to 2499 −25.10
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302d 4002 to 4024 −26.50
gi|208879436|ref|NM_001127461.2| NLRP3 miR-302d 265 to 287 −26.50
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302d 1835 to 1857 −25.10
gi|208879437|ref|NM_001079821.2| NLRP3 miR-302d 3531 to 3553 −26.50
gi|27502389|ref|NM_001562.2| IL18 miR-302d 997 to 1019 −28.50
gi|73622111|ref|NM_033294.2| CASP1 miR-302d 371 to 393 −33.30
gi|73622112|ref|NM_001223.3| CASP1 miR-302d 587 to 609 −33.30
gi|73622114|ref|NM_033292.2| CASP1 miR-302d 650 to 672 −33.30
gi|73622118|ref|NM_033293.2| CASP1 miR-302d 371 to 393 −33.30
gi|27894331|ref|NM_000877.2| IL1R1 miR-576-3p 2803 to 2824 −25.20
75S. Rossi et al. / Genomics 97 (2011) 71–76and genes. Then, we calculated the associations between miRNAs or
clusters of miRNAs or mRNAs and OMIM diseases loci and ﬁnally
validated these through permutations. The ﬁve steps of OMiR are
presented in the Fig. 1. Out of the total number of associations, at 1%
FDR (false discovery rate) we found 5.06%, 8.46% and 10.15%
signiﬁcant associations (Pb0.05) between miRNAs and OMIM IDs ‘*’
or ‘+’, between miRNAs and the ‘#’ preﬁxed OMIM diseases and
miRNAs and the OMIM diseases with a ‘%’ preﬁx, respectively.
The percentages of associations with mRNAs, in the same OMIM IDs
categories were 48.25% (‘*’ or ‘+’), 52.45% (‘#’) and 38.55% (‘%’)
respectively. Based on the generalized hypothesis of 10,000 available
associations, the Fisher exact test between the categories ‘#’ and ‘%’was
Pb0.001, while using all three categories was Pb0.001 (Fig. 2). Table 1
reports the signiﬁcant associations between 10 “orphan” diseases and 6
miRNAs clusters containing 63 miRNAs in total (6.7% of the humanmiRNAs from miRBase 15.0), (Supplemental ﬁle MiRNAs_OMIM_Asso-
ciations.xls reports all found 88 signiﬁcant associations).
Then we explored for 6 of the 88 signiﬁcant ‘%’ associated miRNAs
the mRNAs target terms using DAVID (http://david.abcc.ncifcrf.gov/)
(Table S1; the complete lists of signiﬁcant target terms are reported in
Supplemental Materials (Table S2–S7 for RNA22 predicted targets and
ﬁle miRGen_DAVID.zip for miRGen predicted targets)). In several
instances, the related Gene Ontology, INTERPRO, PATHWAY, UP_TIS-
SUE and SP_PIR_KEYWORDS functional terms were indeed relevant
for the claimed associated disease. Table 1 shows the signiﬁcant
associations obtained for miRNAs associated with ‘%’ by statistical
validation using 10,000 permutations (Pb0.05, FDRb1%). For exam-
ple, the cluster miR-297, miR-302a, miR-302b, miR-302c, miR-302d,
miR-367, miR-376 is signiﬁcantly associated by OMiR to UAQTL1 (uric
acid concentration serum, quantitative trait locus 1), gout
76 S. Rossi et al. / Genomics 97 (2011) 71–76susceptibility 1, longevity 1 and ATFB5 (atrial ﬁbrillation familial 5)
loci, all located in 4q25 chromosomal region. Experimentally, several
PCGs were already found to be involved in the pathogenesis of these
disorders, but none in a causal association: CPPD, CASP1, NALP3, IL-1B
and IL1R for UAQTL1 disease, FOXO3A for longevity and PITX2 for
atrial ﬁbrillation. RNA22 predicted that miR-297 targets FOXO3,
PITX2, IL1B, IL1R, IL18 and CASP1; miR-302a/b/c/d targets FOXO3,
NLRP3 and CASP1 and miR-576-3p targets IL1R (Table 2).
4. Discussion
Traditionally, Mendelian disorders have been classiﬁed as reces-
sive or dominant and by OMIM based on type of known information
about them. However, there is increasing recognition that these
classiﬁcations can be explored to ﬁnd possible candidate for “orphan”
diseases. Here, we investigated the possible association of miRNAs
with human “orphan” diseases. We found 43 miRNA clusters
consisting of about 37.2% (n=349) of all known miRNAs and located
in 80 OMIM ‘%’ loci. The diseases we found signiﬁcantly associated
with the clusters of miRNAs are either associated to a locus, one or
more markers and for few of them, several involved genes are known.
For six of them we presented a functional study as a result of the
integrated analysis of different functional databases (e.g. GO, KEGG
pathways, SP-PIR keywords) provided interesting biological support
to OMiR ﬁndings. As the number of individuals affected by inherited
Mendelian disorders, excluding cancers, are usually small and
therefore the available samples limited, OMIR can be a useful
companion to the scientists for focusing on interesting culprit genes.
Furthermore,with the identiﬁcation of other categories of ncRNAsOMiR
algorithm can be re-run for identiﬁcation of further new possible
“protein-less” non-coding culprits.
Our efforts to identify miRNAs important for diseases without
known pathogeny are not isolated. Recently two papers have been
published with the aim to evaluate human diseases and miRNAs
genomic region associations. Lu and colleagues by manually curating
the published associations, built a human miRNA associated disease
network, suggesting that the appliedmethod can be used in the future
to discover novel disease associations [14]. By using a panel of single-
nucleotide polymorphisms in miRNAs, Muiños-Gimeno and collea-
gues identiﬁed two miRNA regions showing geographical allelic
frequency variation among four HapMAp populations [15]. None of
these studies applied and compared the same method to a large scale
of diseases already associated with a responsible gene or miRNA and
“orphan” disease as we present with OmiR.
5. Conclusion
We devised and implemented OMiR, an algorithm to compute and
study the associations betweenmiRNAs and genetic diseases. We took
advantage of the OMIM database to retrieve disease information.
Additional association options can be implemented to extend the
reach of OMiR, such as the possibility of using markers known by theuser that have not yet been published. Moreover, updating OMiR with
new OMIM IDs and new miRNAs will increase the robustness of the
assay. Our work represents a novel way to extract information on the
relationships between miRNAs and diseases with OMIM IDs not
associated with a speciﬁc disease gene.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2010.10.004.Acknowledgments
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